REGENXBIO (NASDAQ:RGNX – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research note issued to investors on Saturday.
Other equities research analysts also recently issued research reports about the company. Morgan Stanley reaffirmed an “overweight” rating and set a $18.00 price target on shares of REGENXBIO in a report on Friday. Zacks Research lowered shares of REGENXBIO from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Barclays cut shares of REGENXBIO from an “overweight” rating to a “hold” rating in a research note on Friday. Robert W. Baird upped their price target on shares of REGENXBIO from $27.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, June 22nd. Finally, Bank of America lowered their target price on REGENXBIO from $25.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.00.
Check Out Our Latest Report on RGNX
REGENXBIO Stock Performance
REGENXBIO (NASDAQ:RGNX – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.35. The firm had revenue of $108.02 million for the quarter, compared to the consensus estimate of $97.63 million. REGENXBIO had a negative return on equity of 220.07% and a negative net margin of 112.58%. Sell-side analysts predict that REGENXBIO will post -3.96 EPS for the current fiscal year.
Insiders Place Their Bets
In other REGENXBIO news, insider Steve Pakola sold 2,161 shares of REGENXBIO stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $13.64, for a total value of $29,476.04. Following the completion of the sale, the insider owned 213,009 shares in the company, valued at $2,905,442.76. The trade was a 1.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders have sold 58,494 shares of company stock valued at $718,232. 14.22% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Versant Capital Management Inc raised its position in shares of REGENXBIO by 60.4% in the second quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 1,032 shares in the last quarter. Aquatic Capital Management LLC acquired a new stake in REGENXBIO during the third quarter worth approximately $37,000. Captrust Financial Advisors bought a new position in REGENXBIO during the 2nd quarter worth $85,000. Entropy Technologies LP bought a new position in REGENXBIO during the 1st quarter worth $87,000. Finally, Prudential Financial Inc. acquired a new position in REGENXBIO in the 2nd quarter valued at $87,000. Institutional investors and hedge funds own 88.08% of the company’s stock.
Trending Headlines about REGENXBIO
Here are the key news stories impacting REGENXBIO this week:
- Positive Sentiment: Strong Q2 results: REGENXBIO reported earnings of $0.43 per share, well above analyst estimates of $0.08–$0.12, while revenue of $108.0 million exceeded the $97.6 million consensus estimate. The result compares with a $1.38-per-share loss in the year-ago quarter. REGENXBIO Beats Q2 Earnings and Revenue Estimates
- Positive Sentiment: Key pipeline milestones remain on track: The company said its RGX-202 gene therapy filing for Duchenne muscular dystrophy is expected to begin in the third quarter of 2026, with potential accelerated approval in the second half of 2027. RGX-121 for Hunter syndrome is also targeted for resubmission in Q3 2026, while pivotal wet age-related macular degeneration data are expected in Q4 2026. REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
- Positive Sentiment: Improved financial flexibility: More than $200 million of new capital raised in July increased pro forma cash, cash equivalents and marketable securities to over $310 million and extended the cash runway into the fourth quarter of 2027. This reduces near-term financing pressure as the company advances its programs. REGENXBIO Outlines Cash Runway
- Neutral Sentiment: Barclays maintained an Equal Weight rating and set a $12 price target, implying potential upside from recent trading levels but signaling a balanced view rather than a strong bullish recommendation. Barclays Rating Update
- Negative Sentiment: Profitability remains weak: Despite the quarterly beat, REGENXBIO continues to report a deeply negative net margin and return on equity, and analysts expect a full-year loss. Investors may therefore view the earnings improvement as less durable if it depends on licensing or other non-recurring revenue.
- Negative Sentiment: Material execution risk remains: The stock’s valuation and future upside depend heavily on successful regulatory filings, clinical data and eventual commercialization of its gene-therapy programs. Delays, safety concerns or disappointing trial results could pressure RGNX.
REGENXBIO Company Profile
REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.
In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.
Read More
- Five stocks we like better than REGENXBIO
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.
